[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"poor-ovarian-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:poor-ovarian-response":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,77,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100621887","proteomic-and-biological-characterisation-of-plasma-for-the-study-of-changes-following-ovarian-reactivation-treatment-100621887",false,"NCT07376460","Proteomic and Biological Characterisation of Plasma for the Study of Changes Following Ovarian Reactivation Treatment","Biological and Proteomic Characterisation of Platelet-rich Plasma (PRP) Before and After Mobilisation of Haematopoietic Stem Cells in Peripheral Blood From Women With Low Ovarian Response (Low Responders) and in Vitro Evaluation in Human Ovarian Cell Models","Inclusion Criteria:\n\n* Patients aged between 18 and 43.\n* Patients diagnosed with poor ovarian response (POR) or low ovarian reserve according to Bolonia criteria (ESHRE).\n* Patients who are indicated for a StemCell Regenera procedure with the use of granulocyte colony-stimulating factors (Filgrastim).\n* Patients who agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients over the age of 43.\n* Patients with only one ovary.\n* Patients with an autoimmune or haematological disorder.\n* Patients currently undergoing treatment with anticoagulant drugs.\n* Patients who are allergic to Filgrastim, the granulocyte colony-stimulating factor.","FEMALE","18 Years","43 Years",{"count":20,"type":21},10,"ESTIMATED","OBSERVATIONAL","The samples used in PRGF treatments owe their effectiveness to the handling, concentration, and preservation of their components, which explains why samples obtained with different platelet-rich plasma preparation systems may vary. At IVIRMA Group, we employ the closed system PRGF-Endoret to process these samples for StemCell Regenera samples obtained after mobilizing stem cells with granulocyte colony-stimulating factor stimulators. According to current regulations, PRP samples are considered medicinal products by AEMPS, requiring knowledge of the composition of processed samples to be administered to the patient. The study and quantification of samples used in StemCell Regenera treatments aim to understand how stem cell mobilization performed through this technique influences the characteristics of PRGF-Endoret. In this context, the present project aims to systematically analyse the proteomic profile of PRP\u002FPRGF before and after haematopoietic stem cell mobilisation in poor-responder patients, and to evaluate its biological impact in vitro using human ovarian cell models. This approach will enable the identification of key factors involved in ovarian activation and regeneration, thereby providing a mechanistic basis for optimising regenerative therapies applied in clinical reproductive medicine. Furthermore, it will contribute scientifically relevant insights to the field of research and to patients themselves.",[25,26],"Poor Ovarian Response","Ovarian Reactivation",[28,29,30,31,32,33,34,35,36],"Poor ovarian response","ovarian reactivation","StemCell Regenera","ovarian rejuvenation therapy","ovarian failure","Stem cell mobilization","PRP","PRGF","Bone Marrow Derived Stem Cells (BMDSC)","NOT_YET_RECRUITING","2026-02-02",{"date":40,"type":41},"2026-02-04","ACTUAL",{"date":43,"type":21},"2026-02",{"date":45,"type":21},"2026-06",{"name":47,"class":48},"Instituto Valenciano de Infertilidad, IVI Alicante","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100614645","a-rct-study-on-autologous-cell-injection-into-the-ovaries-of-patients-with-por-100614645","NCT07282288","A RCT Study on Autologous Cell Injection Into the Ovaries of Patients With POR","A Randomized Controlled Study on Autologous Cell Injection Into the Ovaries of Patients With Poor Ovarian Response","Inclusion Criteria:\n\n1. Women who have fertility requirements and are seeking IVF treatment\n2. Age ≤ 45 years old, infertility duration ≥ 1 year\n3. Meeting the diagnostic criteria for POI or the Poseidon diagnostic criteria for POR\n4. Previous controlled ovarian stimulation resulted in no more than 3 oocytes retrieved and\u002For no transplantable embryos and\u002For previous embryo implantation failure ≥ 2 times\n5. Uterus and bilateral adnexa are intact\n6. BMI 22 - 29 kg\u002Fm²\n7. Participants must have given informed consent for this study and voluntarily signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Congenital abnormalities of reproductive organs\n2. Septicemia, platelet dysfunction syndrome and severe thrombocytopenia and other coagulation disorders or other hematological diseases\n3. Suffering from autoimmune diseases or other endocrine disorders, with abnormal thyroid function and uncontrolled condition\n4. Having a mass in the adnexal area with an unclear benign or malignant nature\n5. Complicated with severe cardiovascular and cerebrovascular diseases, malignant tumors, hematological diseases and mental disorders, patients with impaired function of important organs\n6. Those who have used systemic corticosteroids within the last 2 weeks, or used antiplatelet drugs such as aspirin within the last 48 hours\n7. In the acute inflammatory stage\n8. Those with a history of venous thrombosis or pulmonary embolism during the screening period","45 Years",{"count":59,"type":21},198,"INTERVENTIONAL",[62],"NA","Poor ovarian response (POR) is a pathological state where the ovaries do not respond well to the stimulation of gonadotropins. It is mainly characterized by a small number of developing follicles, a high cancellation rate of the ovarian stimulation cycle, a low number of retrieved oocytes, and a low clinical pregnancy rate. Premature ovarian insufficiency (POI) is a special type of this condition and is one of the most difficult infertility diseases to treat. The incidence of POR and POI in reproductive-aged women in China is increasing year by year, making them key and challenging issues in reproductive medicine. New local ovarian cell therapy can improve the microenvironment for follicle development, promote the development and ovulation of \"dormant\" primordial follicles, and improve the quality of oocytes. This study intends to conduct autologous fat vascular matrix components (SVF) or autologous platelet-rich plasma (PRP) local injection therapy for patients with POR and POI, and conduct a prospective exploratory study to evaluate the safety of this clinical technique. Subsequently, a prospective randomized controlled trial will be conducted to evaluate the safety and efficacy of autologous fat vascular matrix components (SVF) or autologous platelet-rich plasma (PRP) local injection therapy in improving ovarian reserve and IVF-ET outcomes. This study is expected to improve the fertility of patients with POR from the perspective of autologous cell therapy. The autologous SVF and PRP local injection techniques do not involve ethical barriers, are easy to standardize the diagnosis and treatment process and operation system, and are suitable for clinical translation and promotion.",[25],[28,66,67,68],"Premature ovarian insufficiency","autologous fat vascular matrix components","autologous platelet-rich plasma","2025-12-02",{"date":71,"type":41},"2025-12-15",{"date":71,"type":21},{"date":74,"type":21},"2029-12-01",{"name":76,"class":48},"Peking University Third Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":84,"targetDuration":4,"studyType":60,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100614647","a-rct-study-on-autologous-prp-injection-in-patients-with-por-100614647","NCT07282314","A RCT Study on Autologous PRP Injection in Patients With POR","A Randomized Controlled Study on Autologous Platelet-rich Plasma Injection in Patients With Poor Ovarian Response","Inclusion Criteria:\n\n1. Women who have fertility requirements and are seeking IVF treatment at the Reproductive Medicine Center of Peking University Third Hospital\n2. Age ≤ 45 years old, infertility duration ≥ 1 year\n3. Meeting the diagnostic criteria for POI or the Poseidon diagnostic criteria for POR\n4. Previous controlled ovarian stimulation resulted in no more than 3 oocytes retrieved and\u002For no transplantable embryos and\u002For previous embryo implantation failure ≥ 2 times\n5. Uterus and bilateral adnexa are intact\n6. BMI 18.5 - 29 kg\u002Fm²\n7. Participants must have given informed consent for this study and voluntarily signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Congenital abnormalities of reproductive organs\n2. Septicemia, platelet dysfunction syndrome and severe thrombocytopenia and other coagulation disorders or other hematological diseases\n3. Suffering from autoimmune diseases or other endocrine disorders, with abnormal thyroid function and uncontrolled condition\n4. Having a mass in the adnexal area with an unclear benign or malignant nature\n5. Complicated with severe cardiovascular and cerebrovascular diseases, malignant tumors, hematological diseases and mental disorders, patients with impaired function of important organs\n6. Those who have used systemic corticosteroids within the last 2 weeks, or used antiplatelet drugs such as aspirin within the last 48 hours\n7. In the acute inflammatory stage\n8. Those with a history of venous thrombosis or pulmonary embolism during the screening period",{"count":85,"type":21},142,[62],"Poor ovarian response (POR) is a pathological condition where the ovaries do not respond well to the stimulation of gonadotropins. It is mainly characterized by a low number of developing follicles, a high cancellation rate of the ovarian stimulation cycle, a small number of retrieved oocytes, and a low clinical pregnancy rate. Premature ovarian insufficiency (POI) is a special type of this condition and is one of the most difficult infertility diseases to treat. The incidence of POR and POI in reproductive-aged women in China is increasing year by year, making them key and challenging issues in reproductive medicine. Novel local ovarian cell therapy can improve the microenvironment for follicle development, promote the development and ovulation of \"dormant\" primordial follicles, and improve the quality of oocytes. This study intends to conduct a prospective randomized controlled trial to evaluate the safety and efficacy of autologous platelet-rich plasma (PRP) local injection therapy for improving ovarian reserve and IVF-ET outcomes in patients with POR and POI. This study is expected to improve the fertility of POR patients from the perspective of autologous cell therapy. The autologous PRP local injection technique does not involve ethical barriers, is easy to standardize the diagnosis and treatment process and operation system, and is suitable for clinical translation and promotion.",[25,89],"PRP Injection",[91,68,66],"poor ovarian response",{"date":71,"type":41},{"date":71,"type":21},{"date":95,"type":21},"2029-11-01",{"name":76,"class":48},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":60,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":49},"100565684","application-of-platelet-rich-plasma-prp-in-reproductive-medicine-100565684","NCT06645379","Application of Platelet-rich Plasma (PRP) in Reproductive Medicine","Inclusion Criteria:\n\n* Premature ovarian insufficiency: ① Women aged \\>18 and \\\u003C40 years old; ② Oligomenorrhea or amenorrhea for more than 4 months (excluding pregnancy); ③ Basal follicle stimulating hormone (FSH) \\>25IU\u002FL (interval \\>4 weeks) at least 2 times, or total antral follicles (AFC) \\\u003C5, or anti-Mullerian hormone (AMH) \\\u003C1.1ng\u002FmL.\n* Poor ovarian response: ① Advanced age (≥40 years) or other risk factors for poor ovarian response; ② Poor ovarian response in previous IVF cycle, with ≤3 oocytes retrieved using conventional protocols; ③ Decreased ovarian reserve (antral follicle count \\\u003C5\\~7 or anti-Müllerian hormone \\\u003C0.5\\~1.1 ug\u002FL). Meeting any 2 of the above 3 criteria is sufficient.\n* Intrauterine adhesion: ① Diagnosed by hysteroscopy and scored ≥5 points according to the American Fertility Society criteria (1988); ② With symptoms such as reduced menstrual flow amenorrhea, periodic lower abdominal pain, infertility, or recurrent miscarriage; ③ Adult women with the desire to conceive.\n* Thin endometium: ①Endometrial thickness \\\u003C7mm on ovulation day or on the day of human chorionic gonadotropin (HCG) injection, or \\\u003C7mm on progesterone conversion day when using conventional hormone replacement therapy, ②adult women with the desire to comceive.\n* Repeated implantation failure: Women under 40 years old who have failed to achieve clinical pregnancy after transplanting at least three high-quality embryos within three fresh or frozen cycles. High-quality embryos include: Day 3 embryos (with ≥8 cells, evenly sized blastomeres, and \\\u003C10% fragmentation) and blastocysts (≥3BB).\n\nExclusion Criteria:\n\n* Alanine aminotransferase \\> 3 times the normal upper limit or estimated glomerular filtration rate (EGFR) \\\u003C 90 ml\u002Fmin;\n* Suffering from hemorrhagic diseases (such as hemophilia) or taking anticoagulant or antiplatelet drugs;\n* Suffering from serious mental illness, cardiovascular and cerebrovascular diseases and malignant tumors;\n* Suffering from diabetes with poor blood sugar control or other systemic diseases;\n* Drug abuse, alcoholism or drug addiction;\n* Participated in other interventional clinical studies within half a year;\n* Poor compliance;\n* Other circumstances that are not suitable for participating in the study.","50 Years",{"count":105,"type":21},300,[62],"Female fertility is affected by many factors, such as ovarian function, fallopian tube patency, uterine environment, and mental state, among which the ovaries and endometrium are more important. In reproductive medicine, ovarian dysfunction, poor ovarian reaction, intrauterine adhesion, recurrent implantation failure, and thin endometrium are the five most common diseases that affect fertility. These five diseases lack effective treatment, and previous studies have shown that platelet-rich plasma is promising in treating these five diseases, so it is necessary to further explore the therapeutic effect and potential mechanism.",[109,110,25,111,112],"Premature Ovarian Insufficiency","Intrauterine Adhesion","Repeated Implantation Failure","Thin Endometrium","RECRUITING","2025-02-14",{"date":116,"type":41},"2025-02-18",{"date":118,"type":41},"2024-10-17",{"date":120,"type":21},"2027-09-15",{"name":122,"class":48},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine"]